ECHOIQ Tanks 48% as FDA Rejects Heart Failure Software, but Morgans Sticks to Its Guns

EchoIQ stock fell 48% after the FDA ruled EchoSolv HF not substantially equivalent; a AUD 10M Pro Medicus tranche is tied to clearance.

EchoIQ's Wednesday session will be remembered as one of its ugliest on record. The Australian medtech's shares collapsed 48% to close at 64 cents, having touched 47 cents at the intraday low. Volume told its own story: 53 million shares changed hands, dwarfing a monthly average of under 2.9 million.

The trigger was a regulatory verdict from the US Food and Drug Administration, which ruled EchoIQ's heart failure product EchoSolv HF "Not Substantially Equivalent" under the 510(k) clearance pathway. In plain terms, the agency concluded the system, in its current form, does not yet meet the requirements for market authorization in that specific indication.

Trading in the stock had been halted Monday and Tuesday to prepare the market for the material announcement. The FDA had already communicated its negative determination beforehand, prompting EchoIQ to publish a status update on the application Tuesday. When the shares resumed trading Wednesday, the sell-off was immediate and brutal.

The Funding Domino

The rejection lands squarely on EchoIQ's financing plans. A deal finalized roughly two and a half months ago with Pro Medicus includes a second funding tranche of AUD 10 million that is explicitly tied to successful clearance of EchoSolv HF. With the FDA saying no, that capital is now effectively out of reach until EchoIQ either charts a new regulatory path or delivers the fixes the agency wants.

Investors, it appears, had priced the HF clearance as close to a certainty, which explains the violence of the reaction. A convertible bond financing package arranged more than a month ago had lifted the share price when it was announced — a reminder of how differently the market reads good news and bad.

A Cash Cushion, With a Footnote

EchoIQ is not without resources. Company reports put cash reserves at more than AUD 105 million as of July 2026, a buffer management intends to deploy toward reworking the EchoSolv HF regulatory program. That liquidity is the line between a temporary setback and an existential crisis — and it buys the company time to weigh a revised submission, additional clinical data, or an alternative regulatory strategy.

The next move is a direct dialogue with the FDA. EchoIQ plans to sit down with the agency, digest its detailed feedback, and identify the most efficient route to a fresh filing or a reworked approach. Matthew Dodds, appointed Chief Financial Officer in June, brings more than three decades of medtech and capital markets experience to the financial side of that effort. Separately, 500,000 unlisted employee options lapsed Friday after conditional rights expired, a minor tidying of the capital structure.

What the FDA Decision Doesn't Touch

Management is at pains to note that the rest of the business is unaffected. EchoSolv AS, the company's aortic stenosis detection application, already holds FDA clearance. That designation stands, and EchoIQ is pressing ahead with US commercialization, infrastructure build-out, and reimbursement work for the product as planned.

There was also a fresh positive development on market positioning. S&P DJI announced Friday that EchoIQ will join the ASX 300 Index as part of the quarterly rebalance — a move that typically raises visibility among institutional investors and can support liquidity over time.

Morgans Holds the Line

Perhaps the most striking detail in Wednesday's wreckage is the response from Morgans. Despite the 48% rout, the brokerage maintained its "Speculative Buy" rating and kept its price target at AUD 1.85. The message: the rejection is a serious blow, but the long-term thesis is not dead.

Morgans had issued a buy recommendation on September 1, calling EchoIQ one of the most promising speculative names on the Australian market. Its long-term case rested partly on existing partnerships — the Pro Medicus contracts were finalized about three weeks ago, and the convertible bond package was secured more than a month back to underwrite growth.

The coming weeks should reveal how EchoIQ answers the FDA and whether it can resolve the agency's concerns. Until the regulatory path is clear, the second Pro Medicus tranche stays frozen. Morgans' stance suggests at least part of the market views this episode as a hurdle rather than the end of the story — Wednesday's price action, however, spoke a far more skeptical language.